BRIEF—Aerie given lift ahead of FDA advisory panel meeting

Eye disease specialist Aerie Pharmaceuticals has jumped 15% on the Nasdaq, after the US FDA released documents, ahead of an advisory meeting, in which Rhopressa (netarsudil) was deemed able to effectively reduce eye pressure.

The document states that Rhopressa was effective when administered once per day, but that it was less effective when given twice a day in people with the highest pressure.

The FDA’s advisory panel, which provides non-binding guidance on whether to approve new technologies, will meet in a couple of days to review the drug formally.